CG
XENE icon

Caprock Group’s Xenon Pharmaceuticals XENE Stock Holding History

Caprock Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326K Buy
5,406
+115
+2% +$6.38K 0.01% 1001
2026
Q1 		$308K Buy
5,291
+222
+4% +$10.2K 0.01% 908
2025
Q4 		$227K Buy
+5,069
New +$213K ﹤0.01% 1076

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Caprock Group's XENE Position: Q2 2026 in Review

Caprock Group increased its Xenon Pharmaceuticals (XENE) stake by 2.2% in Q2 2026, buying an estimated $6.38K and bringing the position to 5,406 shares worth $326K. The position accounts for 0.01% of the portfolio, ranked #1001.

Caprock Group first reported a position in XENE in Q4 2025 and has held it in 3 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Caprock Group held 5,406 shares of Xenon Pharmaceuticals worth $326K as of Q2 2026.
  • Caprock Group bought 115 Xenon Pharmaceuticals shares in Q2 2026, an estimated $6.38K.
  • Xenon Pharmaceuticals made up 0.01% of Caprock Group's portfolio in Q2 2026, its #1001 holding.
  • Caprock Group first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.